Business
Rakovina Therapeutics shares new kt-3000 data at American Association of Cancer Research event
(NewsDirect) Rakovina Therapeutics chief scientific officer Mads Daugaard joined Steve Da...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"Rakovina Therapeutics shares new kt-3000 data at American Association of Cancer Research event\n \n \n (NewsDirect)\n \n \n \n \n Rakovina Therapeutics chief scientific\nofficer Mads Daugaard joined Steve Darling from Proactive with news\nthat the company has shared new data at the American Association of\nCancer Research meeting in Orlando, Florida.\n \n \n Daugaard tells Proactive the data\ndescribes the progress of the company’s kt-3000 drug development\nprogram. The data shows the kt-3000 prototype lead candidate exhibits\nhigher PARP-1 versus PARP-2 selectivity compared to the FDA-approved\nPARP inhibitor, olaparib.\n \n \n Daugaard also says the kt-3000 lead\ncandidate effectively reduced lung metastases in mice inoculated with\nEwing sarcoma tumor cells.\n \n \n \n Contact\nDetails\n \n \n \n Proactive Investors\n \n \n +1 604-688-8158\n \n \n \n [email protected]\n \n \n \n Copyright (c) 2023 TheNewswire - All rights reserved.\n \n \n","length":1337,"tagName":"div"}]